~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH.
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has.
Fennec Pharmaceuticals (FENC) Reports FDA Issued Reminder of Non-Substitution of PEDMARK for Pediatric Patients Receiving Cisplatin streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Eli Lilly said its experimental gene therapy restored hearing in a boy born with profound hearing loss. The results for this experimental treatment come three months after Regeneron Pharmaceuticals reported early but encouraging data for its hearing loss gene therapy.
Robert Andrade Sells 15,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.